12 multinational drug companies to release transcripts, see how your home posture?

Medicine Network February 6th, you, presumably just finished the first day of the New Year's workTime is like this, the lively Spring Festival holiday has ended, no matter how nostalgic you are about the past days, and no matter how much you are nostalgic for the good times, the time to go will certainly go, the coming also never absentBut we still have to look back, only to see how the past road came, we can know how the road ahead to go, what skills can continue to insist, what pits can not jumpand in recent days, the world's major pharmaceutical companies are clearly focusing on one thing: the release of its 2016 annual resultsFor pharmaceutical giants, the system combs through the gains and losses of the past year to better develop strategic plans for the new yearBased on history, E Drug managers have reviewed 12 multinational pharmaceutical companies that have now released their 2016 earnings reports to see how the big wigs have performed over the past yearSource: E Pharmaceutical Managers collated1
and $70 billion into win the title based on public information
although some pharmaceuticalcompanies have not reported their 2016 results, there seems to be no suspense about the company's position as sales head in 2016Johnson and Johnson reported sales of $71.89 billion in 2016Although it grew by only 2.6% last year, it has outstripped in absolute terms the combined sales of AbbVie, AstraZeneca and Lilly in 2016for a long time, multinational drug companies in the global sales of the three giants of the throne are basically occupied by Pfizer, Roche, Novartis, the difference may be only in the top three internal position changes But it is clear that such a pattern has been broken in recent years, and the pressure on the former king is enormous The competitive strength of The Strong, which topped the list, surpassed second-place Pfizer's nearly $20 billion in sales Johnson and Johnson's outburst swelled from a surge in its prescription drug business In 2016, Johnson and Johnson's prescription drug business generated $33.46 billion in sales, up 6.5 percent from a year earlier and accounting for nearly half of total revenue But this growth is also mainly reflected in the local market In 2016, Johnson and Johnson's sales in the local market grew by 9.8%, while in the international market it grew by only 1.8%, a slightly smaller margin for a pharmaceutical company, the rapid growth of new products and the steady growth of mature products are critical to performance One of the strongest growth drivers of Johnson and Johnson's 2016 growth came from IMBRUVICA ®, an oral drug used to treat specific B-cell tumor , taken once a day and the world's first BTK inhibitor In addition, Johnson and Johnson's classic SGLT2 inhibitor, Invokana/Inovkamet, used to treat type 2 diabetes, has also grown steadily Johnson and Johnson also had several important products approved in 2016 Darzalex, a new drug for the treatment of multiple myeloma, was approved in the United States and Stelara, which treats adults with moderate to severe kern disease, was approved in Europe Just over a month ago, the FDA approved Johnson's Imbruvica for treatment of lymphoma but in addition to the rapid growth of prescription drug business, the world's largest health care health care products and nursing products companies known as Johnson and Johnson, in the consumer health care business is a constant problem, in addition to the well-known body powder incident, its many products such as children the drug ibuprofen, butalsoin, Merrill Lynch and so on have been exposed to defects In 2016, Johnson and Johnson's consumer health products generated $13.3 billion in revenue, down 1.5% from a year earlier "Do you know what the highest mountain in the world is
2
, and the people of the world are all in the same way "
" Mount Everest! "
" and the second highest? "
..." a well-established view that people will only remember the person at number one But in the fight for supremacy among multinational drug companies, the battle for the top is always a matter of course, and even temporarily in the back place is worth paying attention to such as Baijian, Xinji and Baxter International, which have successfully entered the 10 billion club Sales in 2015 exceeded $10 billion, with full-year revenue of $11.449 billion this year, up 6 percent from a year earlier, and the main source of sales is still coming from areas that have relied on multiple sclerosis, which has been focused on And in the case of Eli and other big men in the field of Alzheimer's drugs are in the environment, Baijian in Phase III of the new Alzheimer's disease drug is also difficult to test New Base is just this year officially entered the 10 billion club, its psoriasis drug Otezla 2016 sales growth of up to 115.6 percent, has become the main sales force , while Pfizer, also in the First Legion, is playing the merger card as usual On September 3, 2015, Pfizer acquired Hessin Ray, On June 24, 2016, Pfizer acquired Anacor Pharmaceuticals, and on September 28, 2016, Pfizer acquired Medivation, which also included the company's contribution in its 2016 financial results But Pfizer also said that excluding the impact, Pfizer's independent operating income also grew by 5 percent in 2016, which is also the growth potential that Pfizer has shown after overcoming the expiration of 2016 product patents and the decline in U.S operating income for adult vaccines of the companies that have now reported earnings, only Novartis and AstraZenresult have reported a decline in revenue Novartis is clearly affected by the decline in Gleevec and Lvcentis, which is not the latest to happen, but as always, Novartis is still investing heavily in research and development, which reached $9,039 million in 2016 For Novartis, despite the current product failure, hope for the future is still there Novartis said in its earnings report that it approved 16 products in 2016 and obtained five breakthrough treatments in the U.S FDA, which is why Novartis is full of information about its product line, including BAF312 (siponimod) for multiple sclerosis and LEE011 (ribolibicic) for breast cancer patients with specific genetic mutations